

## References

### I-112

1. ZALTRAP® (ziv-aflibercept) injection, for intravenous use [package insert]. Sanofi-Aventis. U.S. LLC. Bridgewater, NJ. Revised 12/2020.
2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Colon cancer. Version 2.2016.
3. Ruff P, Cutsem EV, Lakomy R, et al. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. *Journal of Geriatric Oncology*. 2017;1-8.
4. Cutsem EV, Joulian F, Hoff PM, et al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. *Targ Oncol*. 2016;383–400.
5. Clinical Pharmacology™ 2021 Tampa FL: Gold Standard, Inc. Ziv-Aflibercept.
6. National Comprehensive Cancer Network (NCCN). Ziv-aflibercept. NCCN Drugs and Biologics Compendium®. 2021.
7. Nandikolla AG, Rajdev L. Targeting angiogenesis in gastrointestinal tumors: Current challenges. *Transl Gastroenterol Hepatol*. 2016;1:67.
8. Ivanonva JI, Saverno KR, Sung J, Duh MS, Shao C, et al. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. *Med Oncol*. 2017;34(193):1-10.
9. Micromedex DrugDex Compendium®. 2021. Ziv-aflibercept (Zaltrap).
10. Strickler JH, Rushing CN, Niedzwiecki D, et al. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. *BMC Cancer*. 2019;19(1):1-9.

11. Muro, K, Salinardi, T, Singh, A.R, et al. Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. *Cancers* 2020. 12:844.
12. Cleary JM, Horick NK, McCleary NJ, et.al . FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. *Cancer*. 2019;125(13):2213-2221.
13. Buchler T, Kiss I, Hornova J, et al. Sequential treatment with bevacizumab and aflibercept for metastatic colorectal cancer in real-world clinical practice. *Targeted Oncology*. 2020;15(2):193-201.